Emphasys strives for $86m listing
This article was originally published in Clinica
Executive Summary
Emphasys Medical is looking to float on the Nasdaq stock exchange with an $86m public offering. The Redwood City, California-based company will channel the proceeds from the offering to commercialisation of its lead product, the Emphasys bronchial valve (EBV), pending US approval.